High affinity dopamine reuptake inhibitors as potential cocaine antagonists: a strategy for drug development.
The addictive and euphorogenic effects of cocaine are thought to result primarily from inhibition of dopamine reuptake. Although the potency of cocaine-like drugs as inhibitors of DA reuptake is highly correlated with their potency as reinforcers in animals, several potent DA reuptake blockers (bupropion, nomifensine, benztropine, and mazindol) have not been reported to produce addiction or euphoria in humans. Based on these observations in humans, DA reuptake inhibitors are classified into two groups; type 1 blockers, which produce addiction and euphoria, and type 2 blockers, which do not. Given that type 1 and type 2 blockers act at the same site (the DA transporter), the author suggests that type 2 agents may antagonize the effects of cocaine, and might prove useful in the treatment of cocaine addiction.
Rothman
R B
RB
Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20892.
D001590:Benztropine / Q000494:pharmacology; D016642:Bupropion; D003042:Cocaine / Q000037:antagonists & inhibitors*; D004298:Dopamine / Q000378:metabolism*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008454:Mazindol / Q000494:pharmacology; D009627:Nomifensine / Q000494:pharmacology; D011427:Propiophenones / Q000494:pharmacology; D019966:Substance-Related Disorders / Q000188:drug therapy
D011427:Propiophenones; D016642:Bupropion; D009627:Nomifensine; D001590:Benztropine; D008454:Mazindol; D003042:Cocaine; D004298:Dopamine